Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00888927 · ClinicalTrials.gov registry record · Phase 1
Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma
A Phase 1 study, sponsored by Kyowa Kirin Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT00888927 is a Phase 1 study that has completed, run by Kyowa Kirin Co.. The registered enrollment target is 42 participants.
The verdict
NCT00888927, a Phase 1 study, has completed, sponsored by Kyowa Kirin Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
This study will determine the maximum dose of KW-0761 administered intravenously that can be given safely in subjects with previously treated peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma(CTCL)and will see if it is effective in treating the disease.
Interventions
- BIOLOGICAL KW-0761
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2009-05 |
| Est. Completion | 2012-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00888927
The ClinicalTrials.gov registry entry for NCT00888927 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin Co., which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which KW-0761 is the first listed.
NCT00888927 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00888927 about?
NCT00888927 is a clinical study titled "Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma". This study will determine the maximum dose of KW-0761 administered intravenously that can be given safely in subjects with previously treated peripheral T-cell lymphoma (PTCL) or cutaneous T-cell lymphoma(CTCL)and will see if it is effective in treating the disease.
What is the current status of trial NCT00888927?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2009-05. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00888927?
The interventions under investigation include: KW-0761 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00888927?
This trial is sponsored by Kyowa Kirin Co., which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.